Overview

Useful For
Identifying variants within the NAGLU gene

Confirmation of a diagnosis of mucopolysaccharidosis type IIIB

Carrier testing, when there is a family history of mucopolysaccharidosis type IIIB, but disease-causing variants have not been previously identified

Reflex Tests

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>CULFB</td>
<td>Fibroblast Culture for Genetic Test</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Testing Algorithm
If skin biopsy is received, fibroblast culture for genetic test will be performed at an additional charge.

See Lysosomal Storage Disorders Diagnostic Algorithm, Part 1 in Special Instructions.

Special Instructions
- Molecular Genetics: Biochemical Disorders Patient Information
- Informed Consent for Genetic Testing
- Blood Spot Collection Card-Spanish Instructions
- Blood Spot Collection Card-Chinese Instructions
- Informed Consent for Genetic Testing (Spanish)
- Lysosomal Storage Disorders Diagnostic Algorithm, Part 1
- Blood Spot Collection Instructions

Method Name
Polymerase Chain Reaction (PCR) followed by DNA Sequencing

NY State Available
Yes

Specimen

Specimen Type
Varies

Advisory Information
For diagnostic testing or monitoring ongoing therapy, order either MPSBS / Mucopolysaccharidosis, Blood Spot or MPSQU / Mucopolysaccharides Quantitative, Random, Urine.

Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Submit only 1 of the following specimens:

Preferred:

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.
2. Send specimen in original tube.

Specimen Stability Information: Ambient (preferred)/Refrigerated

Specimen Type: Cultured fibroblasts

Container/Tube: T-75 or T-25 flask

Specimen Volume: 1 Full T-75 or 2 full T-25 flasks

Specimen Stability Information: Ambient (preferred)/Refrigerated <24 hours

Specimen Type: Skin biopsy

Supplies: Fibroblast Biopsy Transport Media (T115)

Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.

Specimen Volume: 4-mm punch

Specimen Stability Information: Refrigerated (preferred)/Ambient

Acceptable:

Specimen Type: Blood spot

Supplies: Card - Blood Spot Collection (Filter Paper) (T493)
Container/Tube:

**Preferred:** Collection card (Whatman Protein Saver 903 Paper)

**Acceptable:** Ahlstrom 226 filter paper or Blood Spot Collection Card

**Specimen Volume:** 2 to 5 blood spots on collection card

**Collection Instructions:**

1. An alternative blood collection option for a patient older than 1 year of age is finger stick.
2. Let blood dry on the filter paper at ambient temperature in a horizontal position for 3 hours.
3. Do not expose specimen to heat or direct sunlight.
4. Do not stack wet specimens.
5. Keep specimen dry

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Additional Information:**

1. For collection instructions, see [Blood Spot Collection Instructions](#) in Special Instructions.
2. For collection instructions in Spanish, see [Blood Spot Collection Card-Spanish Instructions](#) (T777) in Special Instructions.
3. For collection instructions in Chinese, see [Blood Spot Collection Card-Chinese Instructions](#) (T800) in Special Instructions.

**Forms**

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:

   - [Informed Consent for Genetic Testing](#) (T576)
   - [Informed Consent for Genetic Testing-Spanish](#) (T826)

2. [Molecular Genetics: Biochemical Disorders Patient Information](#) (T527) in Special Instructions

3. If not ordering electronically, complete, print, and send an [Inborn Errors of Metabolism Test Request](#) (T798) with the specimen.

**Specimen Minimum Volume**

- Blood: 1 mL
- Blood spots: 5 punches, 3-mm diameter

**Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.
**Clinical and Interpretive**

**Clinical Information**

Mucopolysaccharidosis type III (MPS-III), also known as Sanfilippo syndrome, is an autosomal recessive condition that consists of 4 different types (A, B, C, and D). Each type of MPS-III results from the absence of 1 of 4 lysosomal enzymes, which leads to the lysosomal accumulation of heparan sulfatase.

Mucopolysaccharidosis type IIIB (MPS-IIIB), or Sanfilippo syndrome B, is caused by variants in the NAGLU gene and is characterized by reduced or absent activity of the N-acetyl-alpha-D-glucosaminidase. This test screens for variants in all 6 exons of the NAGLU gene.

Sanfilippo syndrome is characterized by severe central nervous system degeneration with only mild physical disease. Onset of clinical features, most commonly behavioral problems and delayed development, usually occurs between 2 and 6 years in a child who previously appeared normal. Severe neurologic degeneration occurs in most patients by 6 to 10 years of age, accompanied by a rapid deterioration of social and adaptive skills. Death generally occurs by the 20s.

Measurement of mucopolysaccharides in blood or urine can aid in diagnosis and ongoing therapeutic monitoring (MPSBS / Mucopolysaccharidosis, Blood Spot or MPSQU / Mucopolysaccharides Quantitative, Random, Urine).

**Reference Values**

An interpretive report will be provided.

**Interpretation**

All detected alterations will be evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations.(1) Variants will be classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

**Cautions**

A small percentage of individuals who are carriers or have a diagnosis of MPS-IIIB may have a variant that is not identified by this method (eg, large genomic deletions, promoter alterations). The absence of a variant, therefore, does not eliminate the possibility of positive carrier status or the diagnosis of MPS-IIIB. The preferred approach to carrier testing is to first document the presence of a variant in the NAGLU gene an affected family member.

In some cases, DNA alterations of undetermined significance may be identified.

Rare polymorphisms exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in the interpretation of results may occur if information given is inaccurate or incomplete.

**Clinical Reference**

---

*Document generated November 30, 2020 at 12:36am CST*
Performance

Method Description
Bidirectional sequence analysis is performed to test for the presence of a variant in all coding regions and intron/exon boundaries of the \textit{NAGLU} gene. (Unpublished Mayo method)

PDF Report
No

Day(s) and Time(s) Test Performed
Performed weekly; Varies

Analytic Time
14 days

Maximum Laboratory Time
20 days

Specimen Retention Time
Whole Blood: 2 weeks (if available); Extracted DNA: 3 months

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to \textit{Test Prices} for detailed fee information.
- Clients without access to Test Prices can contact \textit{Customer Service} 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact \textit{Customer Service}.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
81479-Unlisted molecular pathology procedure
88233-Tissue culture, skin, or solid tissue biopsy (if appropriate)
88240-Cryopreservation (if appropriate)

**LOINC® Information**

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP3BZ</td>
<td>MPS IIIB, Full Gene Analysis</td>
<td>94209-4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>54006</td>
<td>Result Summary</td>
<td>50397-9</td>
</tr>
<tr>
<td>54007</td>
<td>Result</td>
<td>82939-0</td>
</tr>
<tr>
<td>54008</td>
<td>Interpretation</td>
<td>69047-9</td>
</tr>
<tr>
<td>54009</td>
<td>Additional Information</td>
<td>48767-8</td>
</tr>
<tr>
<td>54010</td>
<td>Specimen</td>
<td>31208-2</td>
</tr>
<tr>
<td>54011</td>
<td>Source</td>
<td>31208-2</td>
</tr>
<tr>
<td>54012</td>
<td>Released By</td>
<td>18771-6</td>
</tr>
</tbody>
</table>